dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Trilla-Fuertes, Lucía |
dc.contributor.author | Ghanem, Ismael |
dc.contributor.author | Gámez‑Pozo, Angelo |
dc.contributor.author | Maurel, Joan |
dc.contributor.author | G-Pastrián, Laura |
dc.contributor.author | Mendiola, Marta |
dc.contributor.author | Capdevila Castillon, Jaume |
dc.date.accessioned | 2021-10-22T14:43:22Z |
dc.date.available | 2021-10-22T14:43:22Z |
dc.date.issued | 2020-04 |
dc.identifier.citation | Trilla-Fuertes L, Ghanem I, Gámez-Pozo A, Maurel J, G-Pastrián L, Mendiola M, et al. Genetic profile and functional proteomics of anal squamous cell carcinoma: proposal for a molecular classification. Mol Cell Proteomics. 2020 Apr;19(4):690–700. |
dc.identifier.issn | 1535-9484 |
dc.identifier.uri | https://hdl.handle.net/11351/6458 |
dc.description | Carcinoma anal de cèl·lules escamoses; Biologia molecular; Proteòmica |
dc.description.sponsorship | This study was supported by the Instituto de Salud Carlos III, Spanish Economy and Competitiveness Ministry, Spain and co-sponsored by the FEDER program, “Una forma de hacer Europa” (PI15/01310), a Roche Farma grant, Cátedra UAM-Amgen and a grant of Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD1403). LT-F is supported by the Spanish Economy and Competitiveness Ministry (DI-15–07614). GP-V is supported by the Consejería de Educación, Juventud y Deporte of Comunidad de Madrid (IND2017/BMD7783); AZ-M is supported by Jesús Antolín Garciarena fellowship from IdiPAZ. The authors have declared a conflict of interest. JAFV and AG-P are shareholders in Biomedica Molecular Medicine SL. LT-F and GP-V are employees of Biomedica Molecular Medicine SL. JC has received honoraria for scientific consulting (as speaker and advisory roles) from Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi and Merck Serono and research support from Eisai, Novartis, Ipsen, Astrazeneca, Pfizer and Advanced Accelerator Applications. IG has received honoraria and/or travel expenses from Roche, Sanofi, Merck, Servier, Amgen and Sirtflex, and for advisory role from Merck and Sanofi. JF has received consulting and advisory honoraria from Amgen, Ipsen, Eissai, Merck, Roche and Novartis; research funding from Merck, and travel and accommodation expenses from Amgen and Servier. The other authors declare no conflicts of interest. |
dc.language.iso | eng |
dc.publisher | American Society for Biochemistry and Molecular Biology |
dc.relation.ispartofseries | Molecular & Cellular Proteomics;19(4) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Recte - Càncer - Aspectes genètics |
dc.subject.mesh | Carcinoma, Squamous Cell |
dc.subject.mesh | Anus Neoplasms |
dc.subject.mesh | /genetics |
dc.title | Genetic profile and functional proteomics of anal squamous cell carcinoma: proposal for a molecular classification |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1074/mcp.RA120.001954 |
dc.subject.decs | carcinoma de células escamosas |
dc.subject.decs | neoplasias del ano |
dc.subject.decs | /genética |
dc.relation.publishversion | https://doi.org/10.1074/mcp.RA120.001954 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Trilla-Fuertes L] Biomedica Molecular Medicine SL, C/ Faraday 7, 28049, Madrid, Spain. [Ghanem I] Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain. [Gámez-Pozo A] Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain. [Maurel J] Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Carrer de Villarroel 170, 08036, Barcelona, Spain. [G-Pastrián L] Pathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain. [Mendiola M] Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de Lemos 5, 28029, Madrid, Spain. [Capdevila J] Servei d’Oncologia Mèdica, Vall Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 32107283 |
dc.identifier.wos | 000524532100011 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F01310 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |